Genfit S.A. (GNFT.PA)
EUR 3.5
(2.04%)
EUR 3.5
(2.04%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 173.87 Million EUR | -19.33% |
| 2022 | 215.54 Million EUR | -23.49% |
| 2021 | 281.72 Million EUR | 41.84% |
| 2020 | 198.61 Million EUR | -35.9% |
| 2019 | 309.85 Million EUR | 35.03% |
| 2018 | 229.47 Million EUR | -21.73% |
| 2017 | 293.18 Million EUR | 76.39% |
| 2016 | 166.21 Million EUR | 139.99% |
| 2015 | 69.25 Million EUR | -19.81% |
| 2014 | 86.36 Million EUR | 196.27% |
| 2013 | 29.15 Million EUR | 23.62% |
| 2012 | 23.58 Million EUR | -18.9% |
| 2011 | 29.07 Million EUR | -7.36% |
| 2010 | 31.38 Million EUR | -18.32% |
| 2009 | 38.42 Million EUR | -16.45% |
| 2008 | 45.99 Million EUR | 14.37% |
| 2007 | 40.21 Million EUR | -13.04% |
| 2006 | 46.24 Million EUR | 49.98% |
| 2005 | 30.83 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 194.77 Million EUR | 0.0% |
| 2023 FY | 173.87 Million EUR | -19.33% |
| 2023 Q2 | 193.9 Million EUR | 0.0% |
| 2023 Q4 | 173.87 Million EUR | 0.0% |
| 2022 Q2 | 237.04 Million EUR | 0.0% |
| 2022 FY | 215.54 Million EUR | -23.49% |
| 2022 Q4 | 215.54 Million EUR | 0.0% |
| 2021 Q4 | 281.72 Million EUR | 0.0% |
| 2021 FY | 281.72 Million EUR | 41.84% |
| 2021 Q2 | 133.71 Million EUR | 0.0% |
| 2020 Q4 | 198.61 Million EUR | 0.0% |
| 2020 Q2 | 256.2 Million EUR | 0.0% |
| 2020 FY | 198.61 Million EUR | -35.9% |
| 2019 Q4 | 309.85 Million EUR | 0.0% |
| 2019 Q2 | 323.71 Million EUR | 0.0% |
| 2019 FY | 309.85 Million EUR | 35.03% |
| 2018 Q4 | 229.47 Million EUR | 0.0% |
| 2018 Q2 | 263.63 Million EUR | 0.0% |
| 2018 FY | 229.47 Million EUR | -21.73% |
| 2017 Q4 | 293.18 Million EUR | 0.0% |
| 2017 FY | 293.18 Million EUR | 76.39% |
| 2017 Q2 | 147.4 Million EUR | 0.0% |
| 2016 Q4 | 166.21 Million EUR | 0.0% |
| 2016 FY | 166.21 Million EUR | 139.99% |
| 2016 Q2 | 107.78 Million EUR | 0.0% |
| 2015 Q4 | 69.25 Million EUR | 0.0% |
| 2015 FY | 69.25 Million EUR | -19.81% |
| 2015 Q2 | 76.88 Million EUR | 0.0% |
| 2014 Q4 | 86.36 Million EUR | 0.0% |
| 2014 Q2 | 76.88 Million EUR | 0.0% |
| 2014 FY | 86.36 Million EUR | 196.27% |
| 2013 Q4 | 29.15 Million EUR | 0.0% |
| 2013 Q2 | 34.73 Million EUR | 0.0% |
| 2013 FY | 29.15 Million EUR | 23.62% |
| 2012 Q4 | 23.58 Million EUR | 0.0% |
| 2012 Q2 | 25.85 Million EUR | 0.0% |
| 2012 FY | 23.58 Million EUR | -18.9% |
| 2011 Q2 | 26.37 Million EUR | 0.0% |
| 2011 Q4 | 29.07 Million EUR | 0.0% |
| 2011 FY | 29.07 Million EUR | -7.36% |
| 2010 FY | 31.38 Million EUR | -18.32% |
| 2010 Q4 | 31.38 Million EUR | 0.0% |
| 2010 Q2 | 34.83 Million EUR | 0.0% |
| 2009 FY | 38.42 Million EUR | -16.45% |
| 2009 Q4 | 38.42 Million EUR | 0.0% |
| 2009 Q2 | 42.19 Million EUR | 0.0% |
| 2008 FY | 45.99 Million EUR | 14.37% |
| 2007 FY | 40.21 Million EUR | -13.04% |
| 2006 FY | 46.24 Million EUR | 49.98% |
| 2005 FY | 30.83 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -1081.999% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 46.838% |
| Adocia SA | 24.95 Million EUR | -596.714% |
| Aelis Farma SA | 26.28 Million EUR | -561.588% |
| Biophytis S.A. | 11.93 Million EUR | -1356.702% |
| Advicenne S.A. | 12.4 Million EUR | -1301.402% |
| genOway Société anonyme | 31.84 Million EUR | -446.04% |
| IntegraGen SA | 8 Million EUR | -2073.305% |
| Medesis Pharma S.A. | 1.92 Million EUR | -8926.052% |
| Neovacs S.A. | 47.53 Million EUR | -265.788% |
| NFL Biosciences SA | 3.97 Million EUR | -4278.955% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -1065.915% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -4540.583% |
| Sensorion SA | 46.49 Million EUR | -273.966% |
| Theranexus Société Anonyme | 7.23 Million EUR | -2302.298% |
| TME Pharma N.V. | 2.49 Million EUR | -6880.008% |
| Valbiotis SA | 33.24 Million EUR | -422.955% |
| TheraVet SA | 7.53 Million EUR | -2207.773% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -392.918% |
| argenx SE | 4.11 Billion EUR | 95.772% |
| BioSenic S.A. | 9.55 Million EUR | -1718.935% |
| Celyad Oncology SA | 16.28 Million EUR | -967.879% |
| DBV Technologies S.A. | 165.65 Million USD | -4.963% |
| Galapagos NV | 4.35 Billion EUR | 96.01% |
| GeNeuro SA | 6.31 Million EUR | -2654.233% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | -264.657% |
| Innate Pharma S.A. | 184.19 Million EUR | 5.603% |
| Inventiva S.A. | 69.13 Million EUR | -151.482% |
| MaaT Pharma SA | 42.93 Million EUR | -305.003% |
| MedinCell S.A. | 36.94 Million EUR | -370.586% |
| Nanobiotix S.A. | 93.89 Million EUR | -85.173% |
| Onward Medical N.V. | 43.62 Million EUR | -298.524% |
| Oryzon Genomics S.A. | 106.9 Million EUR | -62.649% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | -112.298% |
| Oxurion NV | 6.55 Million EUR | -2554.534% |
| Pharming Group N.V. | 426.33 Million EUR | 59.217% |
| Poxel S.A. | 4.82 Million EUR | -3505.059% |
| GenSight Biologics S.A. | 9.08 Million EUR | -1813.415% |
| Transgene SA | 45.21 Million EUR | -284.528% |
| Financière de Tubize SA | 1.92 Billion EUR | 90.945% |
| UCB SA | 15.53 Billion EUR | 98.881% |
| Valneva SE | 469.39 Million EUR | 62.958% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -463.988% |